Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment (Q37092266)

18 August 2017

1 reference

title

Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment (English)

1 reference

18 August 2017

0 references

cognitive dysfunction

1 reference

Ivy O Poon

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

1 reference

18 August 2017

page(s)

366-375

1 reference

Global prevalence of dementia: a Delphi consensus study

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I--Factors associated with carer burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

National estimates of the quantity and cost of informal caregiving for the elderly with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Reducing the risk of stroke in elderly patients with hypertension: a critical review of the efficacy of antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Update on hypertension and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

An 18-year follow-up of overweight and risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Midlife blood pressure and dementia: the Honolulu-Asia aging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Antihypertensive medication use and incident Alzheimer disease: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Occurrence of Dementia in Advanced Age: The Study Design of the Kungsholmen Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Reducing the risk of dementia: efficacy of long-term treatment of hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Ca2+ regulation and gene expression in normal brain aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Angiotensin and Alzheimer's disease: therapeutic prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

Care arrangements for people with dementia in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.366

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.3.366

1 reference

18 August 2017

1 reference